EUVIMEDEUVIMED entdecken
Crossref

KASL Consensus Statement for Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatohepatitis: Focus on Semaglutide

Jung Hee Kim, Young Chang, Young-Sun Lee, Miyoung Choi, Won Sohn, Jae Seung Lee, Gwang Hyeon Choi, Soo Jong Yu, Bo Hyun Kim, Seung Up Kim, Won Kim, Dae Won Jun und 8 weitere

Clinical and Molecular Hepatology · 17.11.2026

DOI: 10.3350/cmh.2026.1329 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, online erschienen am 17.11.2026. Verfasst von Jung Hee Kim und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASH) impose a rapidly increasing hepatic and cardiometabolic burden worldwide and in Korea. Following the phase 3 ESSENCE trial, which demonstrated the histological efficacy of semaglutide in noncirrhotic MASH with fibrosis, practical guidance for routine clinical care is needed. The Korean Association for the Study of the Liver developed this expert consensus statement on semaglutide treatment in MASH. Using the RAND/UCLA Appropriateness Method, a 15-member expert panel rated 98 clinical scenarios covering patient selection, dosing, response assessment, adverse event management, and metabolic comorbidities over two rating rounds with a structured panel discussion. Semaglutide is primarily intended for patients with noncirrhotic MASH and stage 2-3 fibrosis. Eligibility should be assessed using a two-step strategy of age-adjusted Fibrosis-4 index screening followed by vibration-controlled transient elastography (VCTE). A VCTE-derived liver stiffness measurement (LSM) of 10-15 kPa defines the preferred treatment range; 15-20 kPa is acceptable when cirrhosis and portal hypertension are excluded, whereas 8-10 kPa requires repeat VCTE, magnetic resonance elastography (eligible range, 3.1-4.4 kPa), or liver biopsy. Semaglutide is initiated at 0.25 mg once weekly and escalated every 4 weeks to a target maintenance dose of 2.4 mg. Response should be assessed with noninvasive tests after at least 18 months; a ≥30% reduction in VCTE-derived LSM suggests response. This consensus provides a structured framework for semaglutide use in MASH, integrated with management of obesity, type 2 diabetes, cardiovascular risk, and chronic kidney disease.

Schlagwörter

Stichwörter der Autor:innen

Expert consensusLiver fibrosisMetabolic dysfunction-associated steatohepatitisNoninvasive testsSemaglutide

Autor:innen und Institutionen

  • Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Gastroenterology and Hepatology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Republic of Korea.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
  • Division of Healthcare Research, National Evidence-based Healthcare Collaborating Agency, Seoul, Republic of Korea.
  • Department of Internal Medicine, Yonsei University College of Medicine, Yonsei Liver Center, Severance Hospital, Seoul, Republic of Korea.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.

Zitieren

APA

Kim, J. H., Chang, Y., Lee, Y. S., Choi, M., Sohn, W., Lee, J. S., Choi, G. H., Yu, S. J., Kim, B. H., Kim, S. U., Kim, W., Jun, D. W., Kim, J. H., Kim, Y. J., Lee, J. W., Cho, Y. K., Park, S. H., Lim, Y. S., Jang, B. K., & Korean Association for the Study of the Liver (KASL) (2026). KASL Consensus Statement for Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatohepatitis: Focus on Semaglutide. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2026.1329

Vancouver

Kim JH, Chang Y, Lee YS, Choi M, Sohn W, Lee JS, et al. KASL Consensus Statement for Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatohepatitis: Focus on Semaglutide. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2026.1329

BibTeX
@article{Kim2026,
  author = {Kim, Jung Hee and Chang, Young and Lee, Young-Sun and Choi, Miyoung and Sohn, Won and Lee, Jae Seung and Choi, Gwang Hyeon and Yu, Soo Jong and Kim, Bo Hyun and Kim, Seung Up and Kim, Won and Jun, Dae Won and Kim, Ji Hoon and Kim, Yoon Jun and Lee, Jin-Woo and Cho, Yong Kyun and Park, Sang Hoon and Lim, Young Suk and Jang, Byoung Kuk and Korean Association for the Study of the Liver (KASL), Korean Association for the Study of the Liver (KASL)},
  title = {KASL Consensus Statement for Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatohepatitis: Focus on Semaglutide},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  doi = {10.3350/cmh.2026.1329}
}
Kostenlos starten →